The effectiveness of an injected caprine serum fraction-immunomodulator (CSF-I2) as a n immunostimulant in male and female F-line and commercial turkey poults infected with fowl cholera (Pasteurella multocida) was examined in separate trials. In the first 2 of 3 controlled trials, the effects of an i.m. injection of CSF-I2 given 24 h prior to a P. multocida challenge, administered by s.c. injection, on mortality and days to death in F-line turkeys was determined. The CSF-I2 reduced mortality but did not affect average number of days to death of F-line turkeys across trials and sexes when administered 24h prior to a P. multocida challenge. In the third trial, the effects of an i.m. injection of CSF-I2 given to a commercial line of turkeys 24h prior to an s.c. injection of P. multocida on mortality and days to death were determined. While positive control commercial turkey poults experienced an 85% level of mortality across sex, the administration of CSF-I2 did not significantly reduce percentage mortality or average number of days to death. The difference in the effects of CSF-I2 on mortality in F-line and commercial turkey poults challenged with P. multocida suggests that CSF-I2 did not impart immunostimulation to commercial turkeys as it did in F-line turkeys that were infected with P. multocida. Therefore, genetic variation in turkeys may be an important consideration before using CSF-I2 as an immunomodulator to protect juvenile turkeys against fowl cholera.
Introduction
Exploration continues in immunological and pharmaceutical research for bio-molecules that may potentiate the immune response in animals. Caprine serum fraction-immunomodulator 2 (CSF-I2), is a non-3 adjuvanted immunostimulant (immunoglobulin, albumin and most cytokines excluded) derived from the serum of adult goats. The material can be lyophilized, reconstituted in water and used as an injectable prophylactic for bacterial challenges. Caprine serum fraction-immunomodulator 2 does not exhibit antimicrobial properties, but it has been shown to be effective in reducing mortality, modulating lymphocyte decreases and heterophil increases and preventing CD + depressions in specific-pathogen-free layer 4 chickens in response to a fowl cholera ( Pasteurella multocida) infection (Willeford et al., 2000) . Furthermore, it has been evaluated for its ability to impart immunostimulation in other species (i.e., mice; Parker et al., 2002) .
Materials and Methods
CSF-I2: Turkey poults selected for increased BW (F-line) have F-line and commercial CSF-I2 trials: The CSF-I2 was been found to be highly susceptible to P. multocida fractionated from adult (> 1 yr of age) goat serum via (Nestor et al., 1999) . The F-line, a sire sub-line of a dialysis at a 6-8kDa cut-off. The material which is 37.5% randombred control line (RBC2), was selected over 31 proteinaceous, was lyophilized to a powder and stored generations for increased 16-wk BW (Nestor, 1977, at -70 C until reconstituted in purified water for use 1984; Nestor et al., 1996) . Li et al. (2000) reported that (Willeford et al., 2000) . Each 1.0mL of injected CSF-I2 male and female 6-wk-old F-line turkey poults exhibited higher mortality and fewer numbers of days to death following challenge with P. multocida than did the RBC2 line. Nestor et al. (1999) also reported that at 6 wk of age, the F-line birds were heavier at the time o f challenge with P. multocida and had higher mortality following challenge with P. multocida than did a line obtained from a commercial breeder. The selection criteria for the sire line used in commercial turkey production was unknown, but was based on increased growth rate. Genetic selection for increased BW i s known to reduce disease resistance in poultry (Saif et al., 1984; Qureshi and Havenstein, 1994) . The goal of the current study was to determine the effectiveness of CSF-I2 in imparting immunostimulation in male and female F-line and commercial turkey poults infected with fowl cholera. o solution contained 20mg/mL of material. Sham CSF-I2 F-line and commercial CSF-I2 trials: At 6 wk of age, injections contained only 1.0mL of purified water. Sham and CSF-I2 solution injections were administered i.m. in the right breast muscle 24h before bacterial challenge.
Bacteria:
F-line and commercial preliminary dosage and CSF-I2 trials: Inocula from field isolates of P. multocida capsular serogroup A, somatic serotype 3, 4 were used. Birds challenged with P. multocida were injected s.c. in the b ack of the neck with 1.0mL of P. multocida inoculum. In the F-line and commercial CSF-I2 trials, P. multocida challenge injections were given 24h after sham or CSF-I2 solution injection. Sham P. multocida injections used in the F-line and commercial CSF-I2 trials contained 1.0mL of sterile broth.
F-line trials:
Bacteria were grown in veal infusion broth for 24h at 37 C and were then washed 3 times with o sterile PBS (pH 7.3), divided into aliquots and stored at -70 C until being thawed for use. Inoculum contained o 1.2x10 bacteria per mL in trial 1 and 1.2x10 bacteria 8 7
per mL in trial 2. The number of bacteria used per bird was as previously specified for 6-wk-old F-line turkey poults (Nestor et al., 1999; Li et al., 2000) . Growth characteristics of the P. multocida isolate used were given by Sacco et al. (1991) .
Commercial preliminary dosage and CSF-I2 trials:
Bacteria were grown in brain-heart infusion broth for 24h at 37 C and 1.0mL of the culture was transferred to a o fresh medium and incubated for 6h. In the preliminary trial, the number of bacteria per mL of fresh inoculum was as specified for each of the 6 treatments and in the CSF-I2 trial, each 1.0mL of fresh inoculum contained approximately 4.5x10 bacteria, which was the 3 approximate concentration at which an 80% level of mortality was attained in the preliminary trial.
Housing, management, and treatments: F-line and commercial preliminary dosage and CSF-I2 trials: All poults were provided ad libitum access to feed and water, and all diets met or exceeded established National Research Council (1994) recommendations for turkey diets. Experimental protocols were approved by Animal Care and Use committees at Ohio State University for the F-line turkey trials and at Mississippi State University for the commercial turkey trials. Poults exhibiting severe clinical morbidity were euthanized by cervical dislocation and were included in the record of mortalities. Birds that remained alive for 14d in the F-line trials and commercial preliminary trial and for 10d in the were kept in one room; from 3-6 wk posthatch, 30 birds CSF-I2 trial after P. multocida challenge at 6 wk were similarly euthanized. turkey poults were subjected to one of the following treatments: 1) Not challenged with P. multocida (sham-injected) and not treated with CSF-I2 solution (shaminjected), 2) Not challenged with P. multocida (sham-injected) and treated with CSF-I2 solution, 3) Challenged with P. multocida and not treated with CSF-I2 solution (sham-injected), or 4) Challenged with P. multocida and treated with CSF-I2 solution. The sexes were intermingled in all pens. Because only one room (unit of replication) was used for treatments 1 and 2, they were not included in the statistical comparison of treatments.
Only treatments 3 and 4 were compared statistically.
F-line trials:
In each of 2 trials, F-line turkey poults were used. Birds were brooded on floor pens in conventional housing, and at 5 wk of age all birds were wing-banded, and those that were challenged with P. multocida at 6 wk of age (treatments 3 and 4) were moved to an isolation facility where they were housed on floor pens. Control birds (treatments 1 and 2) remained on floor pens in the separate conventional housing and were ventilated, fed, and watered separately from the challenged birds to preclude the possibility of a P. multocida infection. The birds were fed the first 2 diets in a multi-diet feeding system with declining protein, as described by Naber and Touchburn (1970) . For treatment 1, there were 13 males and 19 females in an individual pen in trial 1 and 13 males and 20 females in an individual pen in trial 2. For treatment 2, there were 16 males and 16 females in an individual pen in trial 1 and 11 males and 13 females in an individual pen in trial 2. For treatments 3 and 4, there were 3 replicate floor pens per treatment in trial 1, and 2 replicate floor pens per treatment in trial 2. In each trial, there were 6 birds per sex in each replicate pen for treatments 3 and 4.
Commercial preliminary dosage and CSF-I2 trials:
Throughout each trial, commercial turkey poults were raised on litter spread on the floors of isolation rooms within an isolation facility where they were ventilated, fed, and watered separately. All poults were fed basal turkey diets, with compositional adjustments made every 3 wk.
Commercial preliminary dosage trial: The concentration of P. multocida bacteria in inocula necessary to achieve an approximate 80% level o f mortality in 6-wk-old female commercial turkey poults was determined. From 1d to 3 wk posthatch, 60 birds were kept in each of 2 rooms and from 6-8 wk posthatch,treatment. At 6 wk of age, the commercial turkey poults calculated for each sex within each treatment replicate in each of the 6 rooms were challenged with one of the room. The number of days to death following challenge following inoculum treatments, containing different for birds surviving at the end of each trial was numbers of bacteria per mL of inoculum: 1) 1.2x10 , 2) considered as being 10. All birds in each of the 5 P. Commercial CSF-I2 trial: At 2d of age, poults were necropsy, gross anatomical lesions were noted in all separated by sex and placed in 2 different rooms birds that died before or after challenge and fresh liver, according to sex through 2 wk of age and at 2 wk of age, heart and bone marrow samples were cultured from 96 poults (48 males and 48 females) were wing-banded necropsied birds for the specific isolation of P. and randomly assigned to 6 rooms, so that there were multocida. Furthermore, at the end of the trial, all 16 birds in each room (8 males and 8 females). All of remaining live challenged birds were likewise posted for the birds in 5 of the rooms (P. multocida treatment the culturing of tissues and for lesion observation and rooms) were subsequently challenged with P. multocida recording. The 4 birds (2 males and 2 females) from the at 6 wk of age. In addition, 16 control birds (8 males and individual control room were similarly processed. Liver 8 females), which did not receive P. multocida challenge weight was determined in birds that remained alive after injections at 6 wk of age, were maintained in a separate 10 d post-challenge. isolation room (control room). In each of the 5 P. multocida treatment rooms, 4 females and 4 males Statistical analysis for F-line and commercial received sham solution injections and 4 females and 4 preliminary dosage and CSF-I2 trials: In the F-line trials males received CSF-I2 solution injections. At the same (trials 1 and 2), a completely randomized experimental time, 4 females and 4 males similarly received sham or design was used and in the commercial CSF-I2 trial CSF-I2 solution injections in the non-P. multocida (trial 3), a randomized complete block experimental challenge control room.
design was used. In the F-line and commercial CSF-I2
Data collection:
to test for the individual and interactive effects of the 2 F-line trials: During the fifth wk of age, each poult was sexes and the 2 CSF-I2 levels (CSF-I2 vs. no CSF-I2) in weighed and bled via the brachial vein before being birds that were challenged with P. multocida. moved to their respective facilities. A pre-challenge Treatments 1 and 2 in each trial were not included in the ELISA serological test was determined on blood from statistical analysis, because birds in those treatments each bird to ensure a disease-free status. Mortality was were housed in only 1 pen or room. The F-line data were recorded daily in each trial and percentage mortality and analyzed within each trial. Also, employing trial as a average number of days to death were determined block, the F-line data were further analyzed across trials. through 2 wk post-challenge. The number of days to
The data of both trials were pooled then analyzed death following challenge for birds surviving at the end together, with trial considered as a random effect. Data of each trial was considered as being 14.
were subjected to one-way ANOVA when treatment Commercial preliminary dosage trial: For each of the treatment effects within sex were analyzed. Individual inoculum treatments, bird mortality was monitored at sample data within each of the replicate units was least 3 times daily between 6 and 8 wk of age for averaged prior to analysis. Least-squares means were calculation of cumulative percentage mortality. compared using Fisher's protected LSD test in the event Observations for gross anatomical lesions were of significant global effects (Steel and Torrie, 1980) . All conducted on 3-8 birds in each room that were recorded data were analyzed using the MIXED procedure of SAS as mortalities before and after challenge. Fresh liver, software (SAS Institute, 2003) . Global effects and heart, and bone marrow samples were cultured from differences among least-squares means were necropsied birds that were observed for lesions for the considered significant at P < 0.05. specific isolation of P. multocida.
Commercial CSF-I2 trial: Mortality and BW of individual live and dead birds in each room were monitored at least 3 times daily through d 10 post-challenge. Blood samples were collected from 4 tagged birds per room prior to challenge, and at 3, 8, 24, 48, 72, 96 and 120h post-challenge for determination of plasma refractive index. Percentage 10d cumulative mortality and average days to death through d10 post-challenge were alive after 10d post-challenge were necropsied. Upon trials, data were analyzed in a 2x2 factorial arrangement effects across sex, sex effects across treatment, o r
Results

F-line trials:
The ELISA serological tests confirmed that control and challenged birds were negative and positive, respectively, for the presence of P. multocida. Across both trials, there was a significant interaction between sex and CSF-I2 treatment for percentage mortality in Fline turkey poults challenged with P. multocida (P< 0.02). This interaction reflects the occurrence of significant effects due to treatment on percentage mortality of F-line turkey poults across sex in trial 1 (P < 0.02) and trial 2 (P refractive index between 3 and 120h post-challenge. The = 0.04) and across both trials (P < 0.005). Within each trial and in both trials combined, the CSF-I2 significantly reduced mortality across sex in birds challenged with P. multocida (Table 1) . However, there was no significant interaction between sex and CSF-I2 and no significant CSF-I2 treatment main effect on average number of days to death in birds challenged with P. multocida. Nevertheless, there was a significant (P < 0.003) main effect due to sex on average number of days to death. The average days to death across sex was not affected by CSF-I2 in birds challenged with P. multocida in either trial or across both trials (Table 2 ). Percentage mortality was significantly greater in males than in females across treatment in trial 1 (P < 0.02) and across both trials (P < 0.007), but was not significantly greater in males than in females in trial 2 (Table 3) . Furthermore, average days to death was found to be significantly greater in females than in males across treatment in trial 2 (P < 0.03) and across both trials (P < 0.007), but was not significantly greater in females than in males in trial 1 (Table 3) . Across both trials, CSF-I2 significantly reduced mortality in female (P < 0.003) but not in male F-line turkeys challenged with P. multocida (Table 4) . Conversely, across both trials, the average days to death was not significantly affected by CSF-I2 in male or female F-line turkeys challenged with P. multocida (Table 4) .
Commercial preliminary dosage trial:
From the preliminary dosage trial, it was determined that treatment 5 achieved approximately 80% bird mortality. The numbers of bacteria in treatment 5 were approximately 1.2x10 . Gross anatomical lesion 3 observation and fresh liver, heart and bone marrow cultures showed evidence of P. multocida infection and confirmed the presence of P. multocida bacteria i n challenged birds.
Commercial CSF-I2 trial: Typical patterns of morbidity and gross anatomical lesions were observed in all birds that had been challenged with P. multocida; however, birds that had not been challenged appeared normal in all aspects. Furthermore, fresh liver, heart and bone marrow culture tests confirmed that selected control birds that did not receive a P. multocida challenge were negative for P. multocida, whereas swab samples of all 3 tissues tested in all the birds in each of the 5 challenged rooms were positive for the presence of P. multocida. Also, in birds that received a P. multocida challenge, there were no significant interactions between sex and CSF-I2 treatment. There were also no significant main effects due to sex or CSF-I2 treatment on relative liver weight of those birds alive at Day 10 post-challenge, on daily and cumulative changes in BW between 0 and 10d post-challenge, or on plasma only exception was a significant main effect due to sex on change in BW between d2 and 3 post-challenge (P < 0.03). In that time interval, there was a 19g average loss of BW in females and a 105g average increase of BW in males. No mortalities were recorded for birds that were not challenged with P. multocida (treatments 1 and 2). Because only one unit (room) was used to house birds belonging to treatments 1 and 2, those treatments were not included in the statistical comparison of treatments. In trial 3, there were no significant interactions between sex and CSF-I2 treatment and no significant main effects due to sex or CSF-I2 treatment on average percentage 10d cumulative mortality or average days to death through d 10 post-challenge in poults challenged with P. multocida. The administration of CSF-I2 did not significantly reduce percentage mortality across sex in commercial turkey poults challenged with P. multocida (treatments 3 and 4; Table 5 ). Examination of the effects of treatment across sex on mean number of days to death of the turkey poults also revealed that there was no significant effect due to the injection of CSF-I2 prior to P. multocida challenge (treatments 3 and 4; Table 6 ). Analysis of the possible effects of bird sex across treatments 3 and 4 o n percentage mortality and days to death showed that there were no significant differences between sexes for either parameter (Table 7) . Furthermore, when treatment effects were analyzed within each sex separately, it was shown that CSF-I2 did not significantly affect mortality or days to death in either male or female commercial turkey poults challenged with P. multocida (Table 8 ).
Discussion
As evidenced by the results for both percentage mortality and number of days to death, female F-line turkey poults are less susceptible to P. multocida than are males. The difference in the number of bacteria in the challenge inocula used in trials 1 (1.2x10 ) and 2 (1.2x10 ) could 8 7 have led to the differential sex effect on mortality between the 2 trials. A corresponding difference between trials would be expected for days to death; however, because significant effects on both mortality and days to death were not found in trial 1, the 1 log difference in bacteria used between the trials may not have influenced the relationship between sex and mortality or between sex and days to death in challenged birds. The percent mortalities of non-CSF-I2-injected F-line birds in trials 1 and 2 following a P. multocida challenge (94.4 and 95.8%, respectively) further suggest that a 1 log reduction in organism numbers (trial 1-1.2x10 vs. trial 2-8 1.2x10 ) was not sufficient to reduce mortality i n 7 challenged birds. Therefore, should a 50-80% mortality rate after P. multocida challenge be desired for the future testing of CSF-I2 in F-line birds, a greater than 1 log reduction in organism numbers below that used in trial 1 should be considered. Percentage mortality, dead : total birds, and days to death of male and female F-line turkey poults challenged with P. multocida across CSF-I2 treatment (treatments 3 and 4) in trials 1 and 2 and across both trials Trial 1 Trial 2 Both trials Means for each sex within each trial and across both trials for each parameter with no common superscript differ significantly (P < A 1.0mL injection of 20mg/mL CSF-I2 24h prior t o ineffectual despite a significantly higher number of days challenge with P. multocida reduced mortality in the Fto death for females than for males, which was most line poults by more than 20%, which indicates that CSFnotable in trial 2. I2 confers resistance to fowl cholera in the F-line turkeys.
The average percentage of mortality of non-CSF-I2-However, this effect was largely due to a decrease in injected poults across trial in the F-line was 95.0% and female mortality and this occurred despite a lower in the commercial line was 85.0 %. These mortalities mortality in P. multocida-challenged females than were in response to > 1.2x10 and to 4.5x10 bacteria males, which was most evident in trial 1. Although the per 1.0mL of challenge inoculum, respectively. This use of CSF-I2 prior to a P. multocida challenge reduced would suggest that the commercial birds may be more mortality, it did not significantly affect the number of days susceptible to a P. multocida challenge at 6 wk of age to death in the F-line turkeys and its use remained than are F-line birds. This suggestion is in 7 3 disagreement with that of Nestor et al. (1999) , who concluded that mortality following challenge with P. multocida was higher in the F-line than a contemporary commercial line. Nestor et al. (1999) also stated that there may have been variation in resistance among commercial sire lines from the major primary turkey breeders at the time of that study. The differences in the disease resistance between the F and commercial lines observed by Nestor et al. (1999) and those of the current study indicate that the commercial birds used in the 2 studies might also have different levels of disease resistance. The physiological bases underlying these differences have not been determined. Nevertheless, the results of the current trials suggest that 1.0mL i.m. injections of CSF-I2 solutions a t 20mg/mL concentrations 24 h prior to P. multocida challenge at 6 wk of age are effective in reducing mortality in F-line turkey poults, but may be ineffective in reducing mortality in commercial turkey poults. The different resistances of the birds in these 2 lines to the bacterial challenge may have also led to differences in their responses to CSF-I2. Willeford et al. (2000) concluded that one or more small molecular weight compounds isolated from CSF-I2 were able to reduce mortality in specific-pathogen-free layer chickens infected with P. multocida. Although it was stated that the Males Females  ---------------------------------------------------------- Willeford et al. (2000) suggested that one possible route by which CSF-I2 sustains an immunocompetent status is by maintaining the presence of helper T cells in serum. Because serum helper T cell populations were not monitored in any of the current trials, this factor should be investigated in subsequent experiments to help provide a basis o f explanation for the disparity in the effectiveness of CSF-I2 to impart immunostimulation in the F and commercial line turkeys infected with fowl cholera.
